Cipla Hunts For Biotech Partner In China; Calls Off Deal With India's Avesthagen
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - An inordinate delay in the development of three to four biopharmaceuticals by Bangalore-based Avesthagen has led Cipla - India's biggest company in the domestic market - to call off a five-year old partnership and look for joint ventures or collaborations with potential Chinese companies. The disclosure was made to shareholders by Cipla Chairman Yusuf Hamied, at the much-awaited annual general meeting of the company
You may also be interested in...
Cipla Takes To Future Therapies With Stempeutics Pact; Says Preparing For The Big Changes In Research
MUMBAI - Future sciences like monoclonal antibodies or stem cell therapies are not just attracting the fancy of multinational companies scrambling to expand their pipelines; even generic drug makers like India's Cipla are getting drawn into start-up companies and demonstrating an ability to bring to market products that can potentially revolutionalize treatment regimens
Cipla Takes To Future Therapies With Stempeutics Pact; Says Preparing For The Big Changes In Research
MUMBAI - Future sciences like monoclonal antibodies or stem cell therapies are not just attracting the fancy of multinational companies scrambling to expand their pipelines; even generic drug makers like India's Cipla are getting drawn into start-up companies and demonstrating an ability to bring to market products that can potentially revolutionalize treatment regimens
Cipla Forms Joint Venture Company With Chinese Firm For Biosimilars Foray
MUMBAI - India's top generic drug maker, Cipla, is speeding up its entry into biosimilars with the newly named Biomab, an equal stake joint venture with an undisclosed Chinese company